Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹2,420.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹297.81B
Enterprise Value₹349.92B
Total Cash (Recent Filing)₹9.30B
Total Debt (Recent Filing)₹24.56B
Price to Earnings (P/E)139.6
Beta1.41
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityA sustained revenue recovery and a return to net profitability indicate the company has stabilised core operations and can generate positive earnings. Over the medium term this improves capacity to fund R&D, regulatory compliance and working capital internally, reducing reliance on external financing and supporting reinvestment in growth initiatives.
Manageable Leverage & Bigger Equity BaseA steadier debt profile alongside a materially larger equity base strengthens the balance sheet cushion versus prior years. This improves liquidity flexibility, lowers refinancing risk and gives the company scope to absorb shocks or fund capital projects for manufacturing and compliance without immediately pressuring leverage metrics.
Diversified Pharma Revenue StreamsA multi-pronged business model spanning branded formulations, APIs and third‑party manufacturing diversifies revenue and reduces reliance on any single product or geography. Structurally this supports steadier cash flows as contract manufacturing and API sales can offset branded market cyclicality and enable scale benefits over time.
Bears Say
Inconsistent Historical ProfitabilityA history of multi‑year losses and volatile operating profits signals structural earnings inconsistency. Over the medium term this raises risk that profits may revert, making future cash generation and dividend capacity uncertain, and complicating long‑range planning for capex, R&D and market expansion.
Volatile Cash Generation And Low FCFUneven conversion of earnings into free cash flow and a sharp FCF decline limit internal funding for growth and debt reduction. Structurally weak or volatile cash conversion increases reliance on outside capital for investments and heightens vulnerability to working‑capital swings and unexpected regulatory or capex needs.
Dependence On Regulatory ApprovalsA material portion of upside depends on obtaining and maintaining product and plant approvals for regulated markets. This creates structural execution risk: delays or compliance issues can defer revenue, require additional capex and constrain growth visibility, particularly for higher‑margin regulated‑market sales.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹2420.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹297.81B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Aug 07, 2026 which is in 57 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on May 04, 2026. The company reported ₹10.23 earnings per share for the quarter, beating the consensus estimate of N/A by ₹10.23.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹10.23 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.216%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited is a pharmaceutical and biotechnology enterprise specializing in the production and commercialization of active pharmaceutical ingredients, finished drug formulations, biosimilars, and vaccines. Its global footprint encompasses India, the United States, the United Kingdom, Ireland, Mexico, Russia, and other international markets. The company dedicates substantial research and development efforts to discovering new molecules, especially for infectious diseases, with notable projects including WCK 5222, WCK 4282, WCK 4873, WCK 771, WCK 2349, and WCK 6777. Among its biopharmaceutical offerings are Glaritus (an insulin analog), Wosulin (an r-DNA insulin), Wepox (a recombinant erythropoietin used to address anemia linked to cancer and chronic kidney failure), and Biovac-B (a hepatitis B vaccine). Additionally, Wockhardt provides contract manufacturing solutions for sterile injectables, lyophilization, and various other dosage forms, alongside offering specialized research services. Established in 1967, the company maintains its headquarters in Mumbai, India, and functions as a subsidiary of Themisto Trustee Company Private Limited.
Technical Analysis
Ajanta Pharma Limited
―
Alkem Laboratories Ltd.
―
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―